| Literature DB >> 33339897 |
Alexander Jonsson1, Anders Hedin2, Malin Müller2, Oskar Skog2, Olle Korsgren2,3.
Abstract
In experimental studies, pancreatic islet microvasculature is essential for islet endocrine function and mass, and islet vascular morphology is altered in diabetic subjects. Even so, almost no information is available concerning human islet microvascular endothelial cell (MVEC) physiology and gene expression. In this study, islets and exocrine pancreatic tissue were acquired from organ donors with normoglycemia or impaired glucose metabolism (IGM) immediately after islet isolation. Following single-cell dissociation, primary islet- and exocrine MVECs were obtained through fluorescence-activated cell sorting (FACS) and transcriptional profiles were generated using AmpliSeq. Multiple gene sets involved in general vascular development and extracellular matrix remodeling were enriched in islet MVEC. In exocrine MVEC samples, multiple enriched gene sets that relate to biosynthesis and biomolecule catabolism were found. No statistically significant enrichment was found in gene sets related to autophagy or endoplasmic reticulum (ER) stress. Although ample differences were found between islet- and exocrine tissue endothelial cells, no differences could be observed between normoglycemic donors and donors with IGM at gene or gene set level. Our data is consistent with active angiogenesis and vascular remodeling in human islets and support the notion of ongoing endocrine pancreas tissue repair and regeneration even in the adult human.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33339897 PMCID: PMC7749106 DOI: 10.1038/s41598-020-79313-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1(A) Summarized RT-qPCR data for all included sorted samples and associated bulk samples. The sums of the 2^dCT values are used to plot the contribution of each sample type to the total expression of the target genes. Red—islet endothelial cell sample signal, blue—exocrine endothelial cell sample signal, black—bulk (non-sorted) islet tissue signal, white—bulk (non-sorted) exocrine tissue signal. n = 12 (islet bulk), 12 (islet EC), 13 (exocrine bulk) and 13 (exocrine EC). (B) Flow cytometric analysis of sorted cells. Dot plots are presented from one representative sorted islet sample (left—from normo2) and one representative sorted exocrine sample (right—from normo5), indicating that endothelial cells constitute 88% and 91.5% of all cells in these samples. All sorted samples were analyzed and samples closest to the median values were designated representative samples. (C) Deconvolution of RNA-Seq data into estimated proportions of alpha, β, delta, gamma, acinar, ductal, and endothelial cells in exocrine (left) and islet (right) tissue. The proportions were estimated from the raw counts using Multi-subject Single Cell Deconvolution (MuSic). All proportions sum to one. n = 13 (exocrine) and n = 12 (islets).
Figure 2(A) Principal component analysis showing sample variation in two-dimensional principal component space for the sorted islet and exocrine endothelial cell samples. PC1 accounts for 23.09% of the total variation and PC2 16.07% of the total variation exocrine endothelial cell samples. PC1 accounts for 23.09% of the total variation and PC2 16.07% of the total variation. Circles indicate samples from IGM (Impaired Glucose Metabolism) donors, triangles indicate samples from normoglycemic donors. Red indicates islet MVEC samples, blue indicates exocrine MVEC samples. n = 12 (islets) and n = 13 (exocrine). (B) Heatmap with hierarchical clustering of genes and samples using the 1000 genes with the most variance. Color intensity indicates expression level, given as z-score of CPM- TMM- normalized counts. The colored bars on top indicates donor ID, condition (glycemic status) and tissue of origin respectively. A trend towards clustering by tissue of origin is evident. When samples from exocrine and islet cluster together, they originate from the same donor. n = 12 (islets) and 13 (exocrine).
Figure 3(A) Left: Mean difference plot comparing gene expression in islet- and exocrine MVEC samples, displaying log fold change and logCPM. Right: Volcano plot illustrating the logFC and log p-values of the same data, as estimated using a generalized linear model test for differential expression relative to a threshold (glmTREAT). Genes with a fold change of at least 1.2 at FDR < 0.05 are highlighted in red (indicating islet MVEC enrichment) or blue (indicating exocrine MVEC enrichment). n = 12 (islets) and 12 (exocrine). (B) The top enriched gene sets (FDR < 0.01) as determined with gene permutation pre-ranked GSEA, with the x-axis displaying normalized enrichment score (NES) and the color of the bar indicating the FDR q-value. A NES > 0 indicates enrichment in islet MVEC samples, a NES < 0 indicates enrichment in exocrine MVEC samples. n = 12 (islets) and 12 (exocrine). (C) Enrichment map showing relations between enriched gene sets (with FDR < 0.01 and nominal p-value < 0.005) as determined by gene permutation pre-ranked GSEA. Each gene set is represented by a node (red and blue dots for islet MVEC and exocrine MVEC enrichment respectively). Enriched gene sets have been hierarchically clustered, and most clusters (yellow ellipses) have been manually annotated. Edge widths indicate the degree of overlap between gene sets. The sizes of the circles are proportional to the number of genes in the gene set. n = 12 (islets) and 12 (exocrine).
Figure 4Results of the gene permutation pre-ranked gene set enrichment analysis (GSEA) using 14 capillary endothelial cell marker sets derived from the murine endothelial cell atlas. 11 of the sets are dependent on tissue of origin while 3 are biological processes. Normalized Enrichment Score (NES) is indicated by the x-axis. Positive NES values indicate enrichment in islet MVECs, negative NES values indicate enrichment in exocrine MVECs. FDR adjusted p-value is denoted by the color of the dots. The sizes of the gene sets are indicated by the size of the individual dots. n = 12 (islets) and 12 (exocrine).
Organ donor data. CIT, Cold Ischemia Time. IA2A, insulinoma-associated protein 2 autoantibody.
| Donor | Age | Sex | BMI | HbA1C (mmol/mol; %) | CIT (h:m) | Islet purity | IA2A, GADA status | Notes | Insulin release (Dynamic index) | Cause of deatha |
|---|---|---|---|---|---|---|---|---|---|---|
| Normo1 | 75 | F | 31.1 | 35; 5.4 | 13:05 | 99% | Negative | 2.3 | ICH | |
| Normo2 | 70 | F | 40.8 | 42; 6.0 | 4:39 | 92% | Negative | 1.6 | CVL | |
| Normo3 | 39 | M | 26.6 | 34; 5.3 | 14:34 | 78% | n/a | 18.0 | ICH | |
| Normo4 | 62 | M | 22.5 | 29; 4.8 | 17:35 | 91% | n/a | 6.4 | SDH | |
| Normo5 | 68 | F | 26.3 | 40; 5.8 | 23:51 | 87% | Negative | 19.3 | CA | |
| Normo6 | 49 | M | 30.9 | 39; 5.7 | 17:57 | 86% | Negative | n/a | CA | |
| Normo7 | 73 | F | 21.7 | 35; 5.4 | 19:11 | 87% | Negative | 8.9 | TBI | |
| Normo8 | 67 | M | 26.3 | 33; 5.2 | 18:50 | 100% | Negative | Excluded from some analyses b | 1.4 | TBI |
| IGM1 | 58 | M | 30.9 | 48; 6.5 | 11:48 | 83% | n/a | n/a | CI | |
| IGM2 | 78 | F | 22.9 | 69; 8.5 | 18:50 | 92% | Negative | Type 2 diabetes diagnosis, Metformin treatment | 1.2 | ICH |
| IGM3 | 63 | M | 27.8 | 38; 5.6 | 9:08 | 92% | Negative | Type 2 diabetes diagnosis, Metformin treatment | 7.0 | SAH |
| IGM4 | 77 | M | 26.3 | 40; 5.8 | 19:24 | 98% | Negative | Type 2 diabetes diagnosis, Trajenta treatment | 4.1 | CA |
| IGM5 | 55 | M | 30.5 | 46; 6.4 | 15:56 | 91% | Negative | 6.4 | ICH, SAH | |
| Normo mean; IGM mean | 63; 66 | - | 28.3; 27.7 | 36; 48/5.5; 6.6 | 16:13; 15:01 | 90%; 91% | – | 8.3; 4.7 | ||
| Normo median; IGM median | 68; 63 | - | 26.5; 27.8 | 35; 46/5.4; 6.4 | 17:46; 15:56 | 89%; 92% | – | 6.4; 5.3 |
GAD glutamic acid decarboxylase autoantibody, ICH intracerebral hemorrhage, CVL cerebrovascular lesion, SDH subdural hematoma, CA cerebral anoxia following cardiac arrest, TBI traumatic brain injury, CI cerebral infarction, SAH subarachnoid hemorrhage.
aAs entered on the organ donor form.
bIslet sample excluded from all analyses due to low quality reads in islet EC library. Exocrine sample used in PCA, heatmap, and comparisons between donors with normoglycemia and donors with IGM.
Reagent table.
| Reagent | Vendor | Catalog number | Notes |
|---|---|---|---|
| Accutase | Thermo Fisher | A1110501 | |
| CD31 BB515 conjugated antibody, clone WM59 | BD Biosciences | 564630 | RRID:AB_2738872 |
| CD34 BV421 conjugated antibody, clone 581 | BD Biosciences | 562577 | RRID:AB_2687922 |
| CD45 APC-H7 conjugated antibody, clone 2D1 | BD Biosciences | 560,178 | RRID:AB_1645479 |
| MACSQuant Tyto Running Buffer | Miltenyi Biotec | 130-107-206 | |
| Buffer RLT+ | Qiagen | 1,053,393 | Included in the RNeasy Plus Mini-Kit |
| RNeasy Plus Mini-Kit | Qiagen | 74134 | |
| SuperScript VILO cDNA Synthesis Kit | Thermo Fisher | 11754050 | |
| QuantiTect Primer Assays: INS, GCG, AMY2A, PECAM1, VWF, GAPDH, RRN18S | Qiagen | QT01531040, QT00091756, QT01680595, QT00081172, QT00051975, QT01192646, QT00199367 | |
| Ion AmpliSeq Transcriptome Human Gene Expression Kit | Thermo Fisher | A26325 |